Advertisement

Reviews in Endocrine and Metabolic Disorders

, Volume 17, Issue 3, pp 283–286 | Cite as

Skin manifestations of Cushing’s syndrome

  • Constantine A. StratakisEmail author
Article

Abstract

Among the most common diagnostic manifestations of Cushing’s syndrome (CS) are those involving the skin; they include violaceous striae, facial acne, hirsutism, acanthosis nigricans (AN), fungal infections, hyperpigmentation (Hp) and easy bruisability. Fortunately, most resolve within a year or two after cure of CS, although light-colored striae can persist for years depending on the age of the patients. AN, Hp, and bruisability usually resolve within months after cure in almost all ages. Facial plethora (along with acne and other facial skin changes) is a typical sign of CS that is due to increased perfusion. It resolves immediately after curative therapy of CS. Typically, the severity of the manifestations does not correlate with the biochemical indices of the disease, pointing to age, gender, genetic and skin-type differences that determine the cutaneous manifestations of CS.

Keywords

Cushing’s syndrome Glucocorticoids Skin Acne Plethora Hyperpigmentation Bruise Striae Hirsutism Acanthosis 

Notes

Acknowledgements

This review was supported by the research project Z01-HD008920 (Principal Investigator: Dr. Constantine A Stratakis) of the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA.

Compliance with ethical standards

Conflict of interest

The author declares that he has no conflict of interest.

References

  1. 1.
    Stratakis CA, Mastorakos G, Mitsiades NS, Mitsiades CS, Chrousos GP. Skin manifestations of Cushing disease in children and adolescents before and after the resolution of hypercortisolemia. Pediatr Dermatol. 1998;15(4):253–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet. 2003;362(9398):1828–38.CrossRefPubMedGoogle Scholar
  3. 3.
    Schoepe S, Schäcke H, May E, Asadullah K. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol. 2006;15(6):406–20.CrossRefPubMedGoogle Scholar
  4. 4.
    Guillot B. Glucocorticoid-induced cutaneous adverse events. Rev Med Interne. 2013;34(5):310–4.CrossRefPubMedGoogle Scholar
  5. 5.
    Thiboutot DM. Dermatological manifestations of endocrine disorders. J Clin Endocrinol Metab. 1995;80(10):3082–7.PubMedGoogle Scholar
  6. 6.
    Matsuoka LY, Wortsman J, Goldman J. Acanthosis nigricans. Clin Dermatol. 1993;11(1):21–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Feingold KR, Elias PM. Endocrine-skin interactions: cutaneous manifestations of pituitary disease, thyroid disease, calcium disorders and diabetes. J Am Acad Dermatol. 1987;17:921–40.CrossRefPubMedGoogle Scholar
  8. 8.
    Gomez MT, Magiakou MA, Mastorakos G, Chrousos GP. The pituitary corticotroph is not the rate limiting step in the postoperative recovery of the hypothalamic-pituitary-adrenal axis in patients with Cushing syndrome. J Clin Endocrinol Metab. 1993;77(1):173–7.PubMedGoogle Scholar
  9. 9.
    Magiakou MA, Mastorakos GM, Gomez T, Rose SR, Chrousos GP. Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing’s disease. J Clin Endocrinol Metab. 1994;78(1):131–7.PubMedGoogle Scholar
  10. 10.
    Stratakis CA. Cushing syndrome in pediatrics. Endocrinol Metab Clin N Am. 2012 Dec;41(4):793–803.CrossRefGoogle Scholar
  11. 11.
    Gourgari E, Lodish M, Keil M, Wesley R, Hill S, Xekouki P, Lyssikatos C, Belyavskaya E, De La Luz SM, Stratakis CA. Post-operative growth is different in various forms of pediatric Cushing’s syndrome. Endocr Relat Cancer. 2014;21(6):L27–31.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Lodish M, Dunn SV, Sinaii N, Keil MF, Stratakis CA. Recovery of the hypothalamic-pituitary-adrenal axis in children and adolescents after surgical cure of Cushing’s disease. J Clin Endocrinol Metab. 2012;97(5):1483–91.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Stratakis CA, Magiakou MA, Mastorakos G, Passaro M, Oldfield EH, Cutler GB, Chrousos GP. Thyroid function in children with Cushing disease before and after surgical cure. J Pediatr. 1997;131(6):905–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing’s syndrome. Lancet. 2015;386(9996):913–27.CrossRefPubMedGoogle Scholar
  15. 15.
    Lodish MB, Gourgari E, Sinaii N, Hill S, Libuit L, Mastroyannis S, Keil M, Batista DL, Stratakis CA. Skeletal maturation in children with Cushing syndrome is not consistently delayed: the role of corticotropin, obesity, and steroid hormones, and the effect of surgical cure. J Pediatr. 2014;164(4):801–6.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Keil MF, Graf J, Gokarn N, Stratakis CA. Anthropometric measures and fasting insulin levels in children before and after cure of Cushing syndrome. Clin Nutr. 2012;31(3):359–63.CrossRefPubMedGoogle Scholar
  17. 17.
    Briassoulis G, Damjanovic S, Xekouki P, Lefebvre H, Stratakis CA. The glucocorticoid receptor and its expression in the anterior pituitary and the adrenal cortex: a source of variation in hypothalamic-pituitary-adrenal axis function; implications for pituitary and adrenal tumors. Endocr Pract. 2011;17(6):941–8.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Batista DL, Oldfield EH, Keil MF, Stratakis CA. Postoperative testing to predict recurrent Cushing disease in children. J Clin Endocrinol Metab. 2009;94(8):2757–65.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Lodish MB, Hsiao HP, Serbis A, Sinaii N, Rothenbuhler A, Keil MF, Boikos SA, Reynolds JC, Stratakis CA. Effects of Cushing disease on bone mineral density in a pediatric population. J Pediatr. 2010;156(6):1001–5.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Keil MF, Merke DP, Gandhi R, Wiggs EA, Obunse K, Stratakis CA. Quality of life in children and adolescents 1-year after cure of Cushing syndrome: a prospective study. Clin Endocrinol. 2009;71(3):326–33.CrossRefGoogle Scholar
  21. 21.
    Michelson D, Stratakis CA, Hill L, Reynolds J, et al. Bone mineral density in women with depression. N Engl J Med. 1996;335:1176–81.CrossRefPubMedGoogle Scholar
  22. 22.
    Arem AJ, Kirscher CW. Analysis of striae. Plast Reconstr Surg. 1980;65:22–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Serres M, Viac J, Schmitt DB. Glucocorticoid receptor localization in human epidermal cells. Arch Dermatol Res. 1996;288:140–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Chedid M, Hoyle JR, Csaky KG, Rubin JS. Glucocorticoids inhibit keratinocyte growth factor production in primary dermal fibroblasts. Endocrinology. 1996;137:2232–7.PubMedGoogle Scholar
  25. 25.
    Meisler N, Shull S, Xie R, Long GL, Asher M, Connoly JP, Cutroneo KR. Glucocorticoids coordinately regulate type I collagen pro-alpha 1 promoter activity thorugh both the glucocorticoid and TGF-b response elements: a novel mechanism of glucococrtocid regulation of eukaryotic genes. J Cell Biochem. 1995;59:376–88.CrossRefPubMedGoogle Scholar
  26. 26.
    Brauchle M, Fassler R, Werner S. Suppression of keratinocyte growth factor expression by glucocorticoids in vitro and during wound healing. J Invest Dermatol. 1995;105:579–84.CrossRefPubMedGoogle Scholar
  27. 27.
    Haapasaari KM, Risteli J, Oikarinen A. Recovery of human skin collagen synthesis after short-term topical corticosteroid treatment and comparison between young and old subjects. J Dermatol. 1996;135:65–9.CrossRefGoogle Scholar
  28. 28.
    McMichael AJ, Griffiths CE, Talwar HS, Finkel LJ, Rafal ES, Hamilton TA, Voorhees JJ. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. Br J Dermatol. 1996;135:60–4.CrossRefPubMedGoogle Scholar
  29. 29.
    Nesbitt Jr LT. Minimizing complications from systemic glucocorticoid use. Dermatol Clin. 1995;13:925–39.PubMedGoogle Scholar
  30. 30.
    Bouzas EA, Mastorakos G, Friedman TC, Scott MH, Chrousos GP, Kaiser-Kupfer MI. Posterior subcapsular cataract in endogenous Cushing syndrome: an uncommon manifestation. Invest Ophthalmol Vis Sci. 1993;34:3497–500.PubMedGoogle Scholar
  31. 31.
    Afshari A, Ardeshirpour Y, Lodish MB, Gourgari E, Sinaii N, Keil M, Belyavskaya E, Lyssikatos C, Chowdhry FA, Chernomordik V, Anderson AA, Mazzuchi TA, Gandjbakhche A, Stratakis CA. Facial plethora: modern technology for quantifying an ancient clinical sign and its use in Cushing syndrome. J Clin Endocrinol Metab. 2015;100(10):3928–33.Google Scholar
  32. 32.
    Hannah-Shmouni F, Stratakis CA, Koch CA. Flushing in (neuro)endocrinology. Rev Endocr Metab Disord. 2016. doi: 10.1007/s11154-016-9394-8.

Copyright information

© Springer Science+Business Media New York (outside the USA) 2016

Authors and Affiliations

  1. 1.Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of HealthBethesdaUSA

Personalised recommendations